David Wagner

Dr. David Wagner


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 March 2024 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Closed access
WLWenkui Li
Wenkui Li
FVFaye Vazvaei‐Smith
Faye Vazvaei‐Smith
GDGordon Dear
Gordon Dear
JBJason Boer
Jason Boer
FCFilip Cuyckens
Filip Cuyckens
XXXiaohui (Sophia) Xu
Xiaohui (Sophia) Xu

23 September 2022 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
ABAndrew Bowman
Andrew Bowman
JSJames Sawicki
James Sawicki
NTNari Talaty
Nari Talaty
WBWayne R. Buck
Wayne R. Buck
JYJunhai Yang
Junhai Yang
DWDavid Wagner
David Wagner
(1) Imaging of pharmaceutical compounds in tissue is an increasingly important subsection of Mass Spectrometry Imaging (MSI). Identifying proper target engagement requires MS platforms with high sensitivity and spatial resolution. Three prominent categories of drugs are small molecule drugs, antibody-drug conjugate payloads, and protein degraders. (2) We tested six common MSI platforms for their limit of detection (LoD) on a representative compound for each category: a Matrix-Assisted Laser Desorption/Ionization (MALDI) Fourier Transform Ion Cyclotron, a MALDI-2 Time-of-Flight (ToF), a MALDI-2 Trapped Ion Mobility Spectrometry ToF, a Desorption Electrospray Ionization Orbitrap, and 2 Atmospheric Pressure-MALDI Triple Quadrupoles. Samples were homogenized tissue mimetic models of rat liver spiked with known concentrations of analytes. (3) We found that the AP-MALDI-QQQ platform outperformed all 4 competing platforms by a minimum of 2- to 52-fold increase in LoD for representative compounds from each category of pharmaceutical. (4) AP-MALDI-QQQ platforms are effective, cost-efficient mass spectrometers for the identification of targeted analytes of interest.

10 April 2024 in Pharmacology Research & Perspectives
Verified
Journal Article
Open access
JSJohn P. Savaryn
John P. Savaryn
RSRichard L. Smith
Richard L. Smith
MRMatthew Rosebraugh
Matthew Rosebraugh
MNMelina Neenan
Melina Neenan
RBRichard Burton
Richard Burton
DWDavid Wagner
David Wagner
Analysis was conducted to compare levodopa/carbidopa pharmacokinetics and drug‐related material in plasma of healthy participants after receiving a continuous infusion of Levodopa/Carbidopa Intestinal Gel (LCIG) to a continuous subcutaneous infusion of foslevodopa/foscarbidopa. Study samples were from a randomized, open‐label, 2‐period crossover study in 20 healthy participants. Participants received either 24‐h foslevodopa/foscarbidopa SC infusion to the abdomen or LCIG delivered for 24 h to the jejunum through a nasogastric tube with jejunal extension. Serial blood samples were collected for PK. Comparability of the LD PK parameters between the two treatment regimens was determined. Selected plasma samples were pooled per treatment group and per time point for metabolite profiling. LC–MSn was performed using high‐resolution mass spectrometry to identify drug‐related material across the dosing regimens and time points. The LD PK parameter central values and 90% confidence intervals following the foslevodopa/foscarbidopa subcutaneous infusion were between 0.8 and 1.25 relative to the LCIG infusion. With LCIG administration, LD, CD, 3‐OMD, DHPA, DOPAC, and vanillacetic acid were identified in plasma at early and late time points (0.75 and 24 h); the metabolic profile after administration of foslevodopa/foscarbidopa demonstrated the same drug‐related compounds with the exception of the administered foslevodopa. 3‐OMD and vanillacetic acid levels increased over time in both treatment regimens. Relative quantification of LC–MS peak areas showed no major differences in the metabolite profiles. These results indicate that neither the addition of monophosphate prodrug moieties nor SC administration affects the circulating metabolite profile of foslevodopa/foscarbidopa compared to LCIG.

12 January 2024 in Drug Metabolism and Disposition
Verified
Journal Article
Open access
PDF file
FCFilip Cuyckens
Filip Cuyckens
MHMette G. Hvenegaard
Mette G. Hvenegaard
KCKenneth C. Cassidy
Kenneth C. Cassidy
DSDouglas K. Spracklin
Douglas K. Spracklin
AJAlexander D. James
Alexander D. James
GYGraeme C. Young
Graeme C. Young
The administration of radiolabeled drug candidates is considered the gold standard in absorption, distribution, metabolism and excretion (ADME) studies for small molecule drugs, since it allows facile and accurate quantification of parent drug, metabolites and total drug related material independent of the compound structure. The choice of the position of the radiolabel, typically 14C or 3H, is critical to obtain relevant information. Sometimes a biotransformation reaction may lead to cleavage of a part of the molecule. As a result only the radiolabeled portion can be followed while information on the fate of the non-labeled metabolite may be lost. Synthesis and administration of two or more radiolabeled versions of the parent drug as a mixture or in separate studies may resolve this issue, but comes with additional challenges. In this paper we address the questions that may be considered to help make the right choice whether to use single or a multiple radiolabel approach, discuss pros and cons of different multiple labeling strategies that can be taken as well as alternative methods that allow the non-labeled part of the molecule to be followed. Significance Statement Radiolabeled studies are the gold standard in drug metabolism research, but molecules can undergo cleavage with loss of the label. This often results in discussions around potential use of multiple labels which seem to be occurring with increased frequency since an increasing proportion of the “small molecule drugs” are tending towards larger molecular weights. This review provides insight and decision criteria in considering a multiple label approach as well as pros and cons of different strategies that can be followed.

7 October 2022 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
JYJunhai Yang
Junhai Yang
LRLauren Rendino
Lauren Rendino
SCSteven Cassar
Steven Cassar
WBWayne Buck
Wayne Buck
JSJames Sawicki
James Sawicki
DWDavid Wagner
David Wagner
The utility of zebrafish is becoming more frequent due to lower costs and high similarities to humans. Zebrafish larvae are attractive subjects for drug screening and drug metabolism research. However, obtaining good quality zebrafish larvae sections for batch samples at designated planes, angles, and locations for comparison purposes is a challenging task. We report here the optimization of fresh frozen zebrafish larvae sectioning for mass spectrometry imaging. We utilized the gelatin solutions that were created at two different temperatures (50 and 85 °C) as embedding media. Gelatin-50 (gelatin created under 50 °C, solid gel under room temperature) was used to make a larvae-shaped mold and gelatin-85 (gelatin created under 85 °C, liquid under room temperature) was used to embed the larvae. H&E staining of sections shows well-preserved morphology and minimal histological interference. More importantly, the position of the larvae was well controlled resulting in more consistent sectioning of the larvae.

22 December 2023 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Open access
GYGraeme C. Young
Graeme C. Young
DSDouglas K. Spracklin
Douglas K. Spracklin
AJAlexander D. James
Alexander D. James
MHMette G. Hvenegaard
Mette G. Hvenegaard
MPMette L. Pedersen
Mette L. Pedersen
GSGraeme Scarfe
Graeme Scarfe
A review of the use of microdoses and isotopic microtracers for clinical intravenous pharmacokinetic (i.v. PK) data provision is presented. The extent of application of the varied approaches available and the relative merits of each are highlighted with the aim of assisting practitioners in making informed decisions on the most scientifically appropriate design to adopt for any given new drug in development. It is envisaged that significant efficiencies will be realized as i.v. PK data in humans becomes more routinely available for suitable assets in early development, than has been the case prior to the last decade.